The Nlrp3 inflammasome admits defeat.

The Nlrp3 inflammasome triggers interleukin-1 secretion by myeloid cells in response to endogenous and exogenous danger signals. Two recent studies identified the sulfonylurea MCC950 and the ketone metabolite β-hydroxybutyrate as specific inhibitors of the Nlrp3 inflammasome, with promising therapeutic potential for the treatment of auto-inflammatory diseases.